Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

hAd5-HPV Vaccine

Vaccine (Adenoviral vector) · Immune activation, directed at HPV E6/E7 · developed by ImmunityBio

Phase 2 Most advanced trial
IBRX Developer
1 Registered trials

What is hAd5-HPV Vaccine?

hAd5-HPV is an adenovirus-based vaccine encoding HPV E6/E7 antigens, administered subcutaneously. It is being studied in HPV-positive oropharyngeal squamous cell carcinoma and head and neck cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Vaccine (Adenoviral vector)
Targets
HPV E6/E7 (antigen)
Mechanism
Immune activation, directed at HPV E6/E7
Therapy area
Oncology
Developer
ImmunityBio, Inc. (IBRX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07628062 Phase 2 HPV-Positive Oropharyngeal Squamous Cell Carcinoma Not yet recruiting IBRX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Head and Neck CancerHPV-Positive Oropharyngeal Squamous Cell CarcinomaOropharyngeal Squamous Cell Carcinoma

More from ImmunityBio

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the IBRX page.

Follow IBRX, the company behind hAd5-HPV Vaccine

See IBRX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

IBRX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.